Condition: Metastatic Castration-Resistant Prostate Cancer · Prostate Cancer Patients With Bone Metastasis · Prostate Cancer (CRPC) · Sponsor: Ebrahim S Delpassand
The purpose of this study is to evaluate the safety and tolerability of Lutetium-177-PSMA-617 (PLUVICTO) in patients with metastatic castration-resistant prostate cancer (mCRPC) and extensive bone metastases, which appear as a "super scan" pattern on a bone scan. Pluvicto is FDA-approved, but patients with super scan bone scans were previously excluded from the VISION clinical trial, leaving a knowledge gap. The study will enroll up to 30 men with metastatic castration-resistant prostate cancer, with an initial dosing approach that differs from the standard dose. The safety and tolerability of PLUVICTO will be evaluated in this study, with a focus on identifying the optimal dose for this population. This study addresses an important gap in understanding how Pluvicto performs in mCRPC patients with super scan findings.
This description comes directly from the study's public registry record.
Susan Cork Therapy Coordinator · 713-781-6200 · scork@exceldiagnostics.com
Nereyda Sauceda, Therapy Coordinator · 713-781-6200 · nsauceda@exceldiagnostics.com
Always discuss trial participation with your own doctor first.
| Excel Diagnostics & Nuclear Oncology Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06972628